Literature DB >> 16382538

A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor.

S J Frucht1, W C Houghton, Y Bordelon, P E Greene, E D Louis.   

Abstract

The authors performed an open-label, rater-blinded, add-on study of sodium oxybate in 20 patients with ethanol-responsive myoclonus or essential tremor. Blinded ratings of videotaped examinations showed improvements in myoclonus at rest, stimulus-sensitive myoclonus, action myoclonus, functional performance, and postural and kinetic tremor. Tolerability was acceptable, and more than half of the patients chose to continue treatment after the trial. Double-blind placebo-controlled studies in these disorders are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16382538

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

Review 1.  An update and review of the treatment of myoclonus.

Authors:  Kelly Mills; Zoltan Mari
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

Review 2.  Pharmacotherapy of essential tremor : an overview of existing and upcoming agents.

Authors:  Kelly E Lyons; Rajesh Pahwa
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Effect of γ-hydroxybutyrate (GHB) on driving as measured by a driving simulator.

Authors:  Evangelia Liakoni; Delia A Dempsey; Matthew Meyers; Nancy G Murphy; Dary Fiorentino; Christopher Havel; Christine Haller; Neal L Benowitz
Journal:  Psychopharmacology (Berl)       Date:  2018-09-19       Impact factor: 4.530

Review 4.  gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness.

Authors:  Daniel Pardi; Jed Black
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Diagnosis and management of essential tremor and dystonic tremor.

Authors:  Alexandre Gironell; Jaime Kulisevsky
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 6.  An update on essential tremor.

Authors:  Rodger J Elble; Günther Deuschl
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

Review 7.  Linking Essential Tremor to the Cerebellum: Neurochemical Evidence.

Authors:  Juan Marin-Lahoz; Alexandre Gironell
Journal:  Cerebellum       Date:  2016-06       Impact factor: 3.847

Review 8.  Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.

Authors:  Lawrence P Carter; Daniel Pardi; Jane Gorsline; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-06-02       Impact factor: 4.492

Review 9.  Physiology-Based Treatment of Myoclonus.

Authors:  Ashley B Pena; John N Caviness
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 10.  Comparative genomics of aldehyde dehydrogenase 5a1 (succinate semialdehyde dehydrogenase) and accumulation of gamma-hydroxybutyrate associated with its deficiency.

Authors:  Patrizia Malaspina; Matthew J Picklo; C Jakobs; O Carter Snead; K Michael Gibson
Journal:  Hum Genomics       Date:  2009-01       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.